Anti-Ulcer Agents

• 

  Subject Areas on Research

  • A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. 
  • A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. 
  • Advances in drug therapy for peptic ulcer disease. 
  • An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. 
  • Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. 
  • Antiulcer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines. 
  • Antiulcer agents. 2. Gastric antisecretory, cytoprotective, and metabolic properties of substituted imidazo[1,2-a]pyridines and analogues. 
  • Antiulcer agents. 4. Conformational considerations and the antiulcer activity of substituted imidazo[1,2-a]pyridines and related analogues. 
  • Attenuation of acid induced oesophagitis in VR-1 deficient mice. 
  • Bariatric Embolization: Pilot Study on the Impact of Gastroprotective Agents and Arterial Distribution on Ulceration Risk and Efficacy in a Porcine Model. 
  • Endoscopy, nonsteroidal anti-inflammatory drug, and omeprazole regimen in colorectal cancer prevention. 
  • Follow-up care after a diagnosis of Helicobacter pylori infection in an Asian immigrant cohort. 
  • Gastropathy induced by nonsteroidal anti-inflammatory drugs: prescribing patterns among geriatric practitioners. 
  • Geranyl-geranyl acetone: a novel stimulant of secretin release in the dog. 
  • Hydroxychloroquine-induced hyperpigmentation: the staining pattern. 
  • Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. 
  • Nonsteroidal antiinflammatory drug use among patients with GI bleeding. 
  • Omeprozole therapy in pediatric patients after liver and intestinal transplantation. 
  • PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. 
  • Pediatrician approach to dysphonia. 
  • Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study.